Results 61 to 70 of about 5,474,833 (393)

UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer

Cell Death and Disease, 2021
UPF1 is proved to dysregulate in multiple tumors and influence carcinogenesis. However, the role of UPF1 in oxaliplatin resistance in colorectal cancer (CRC) remains unknown.
Congcong Zhu, Long Zhang, Senlin Zhao, Weixing Dai, Yun Xu, Yuqin Zhang, Hongtu Zheng, Weiqi Sheng, Ye Xu   +8 more
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Prognostic nomograms for predicting cause-specific survival and overall survival of stage I–III colon cancer patients: a large population-based study

Cancer Cell International, 2019
Background The purpose of this study was to build functional nomograms based on significant clinicopathological features to predict cause-specific survival (CSS) and overall survival (OS) in patients with stage I–III colon cancer.
Zheng Zhou, Shaobo Mo, Weixing Dai, Wenqiang Xiang, Lingyu Han, Qingguo Li, Renjie Wang, Lu Liu, Long Zhang, Sanjun Cai, Guoxiang Cai   +10 more
doaj   +1 more source

Clinical Value of Abnormal Prothrombin Combined with CEA, CA72-4 and CA199 on Patients with Gastric Cancer

Zhongliu Fangzhi Yanjiu, 2018
Objective To evaluate the clinical value of abnormal prothrombin (PIVKA-Ⅱ) combined with CEA, CA199 and CA72-4 on the diagnosis, treatment, recurrence and metastasis of patients with gastric cancer. Methods Serum PIVKA-Ⅱ, CEA, CA72-4, CA199 levels in 123
CAI Xiaojuan, WANG Kun, YU Jing
doaj   +1 more source

Risk of non‐colorectal cancer‐related death in elderly patients with the disease: A comparison of five preoperative risk assessment indices

Cancer Medicine, 2023
Background A considerable number of elderly patients with colorectal cancer (CRC) die of non‐CRC‐related causes. The Controlling Nutritional Status (CONUT) score, American Society of Anesthesiologists Physical Status classification, Charlson Comorbidity ...
Kohei Yasui, Dai Shida, Yuka Ahiko, Yasuyuki Takamizawa, Konosuke Moritani, Shunsuke Tsukamoto, Yukihide Kanemitsu   +6 more
doaj   +1 more source

Radiotherapy and Chemotherapy for Colorectal Cancer [Abridged] [PDF]

, 1973
George Crile
  +6 more sources

Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer [PDF]

, 2017
Purpose: DEAD box protein 3 (DDX3) is an RNA helicase with oncogenic properties that shuttles between the cytoplasm and nucleus. The majority of DDX3 is found in the cytoplasm, but a subset of tumors has distinct nuclear DDX3 localization of yet unknown ...
Bol, Guus M., Buerger, Horst, Heerman van Voss, Marise R., Meeldijk, Jan, Offerhaus, G. Johan, Patel, Arvind H., Raman, Ana, Raman, Venu, van der Wall, Elsken, van Diest, Paul J., Vesuna, Farhad   +10 more
core   +2 more sources

A Rare Complication After Laparoscopic Lateral Lymph Node Dissection for Rectal Cancer: Two Case Reports of Internal Hernia Below the Superior Vesical Artery

Journal of the Anus, Rectum and Colon, 2018
Total mesorectal excision or mesorectal excision with lateral lymph node dissection (LLND) is a standard treatment for locally advanced lower rectal cancer in Japan.
Daichi Kitaguchi, Yuji Nishizawa, Takeshi Sasaki, Yuichiro Tsukada, Akihiro Kondo, Hiro Hasegawa, Masaaki Ito   +6 more
doaj   +1 more source

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

New England Journal of Medicine, 2004
BACKGROUND The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR.
D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, E. Van Cutsem   +11 more
semanticscholar   +1 more source

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).

Journal of Clinical Oncology, 2020
PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab in a dose-finding part to estimate the maximum tolerated dose.
S. Fukuoka, H. Hara, N. Takahashi, T. Kojima, A. Kawazoe, M. Asayama, T. Yoshii, D. Kotani, H. Tamura, Y. Mikamoto, N. Hirano, M. Wakabayashi, S. Nomura, A. Sato, T. Kuwata, Y. Togashi, H. Nishikawa, K. Shitara   +17 more
semanticscholar   +1 more source